Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 135

1.

A phase I study of panobinostat and ruxolitinib in patients with primary myelofibrosis (PMF) and post--polycythemia vera/essential thrombocythemia myelofibrosis (post--PV/ET MF).

Mascarenhas J, Marcellino BK, Lu M, Kremyanskaya M, Fabris F, Sandy L, Mehrotra M, Houldsworth J, Najfeld V, El Jamal S, Petersen B, Moshier E, Hoffman R.

Leuk Res. 2020 Jan;88:106272. doi: 10.1016/j.leukres.2019.106272. Epub 2019 Nov 16.

PMID:
31778911
2.

Pegylated interferon alfa-2a for polycythemia vera or essential thrombocythemia resistant or intolerant to hydroxyurea.

Yacoub A, Mascarenhas J, Kosiorek H, Prchal JT, Berenzon D, Baer MR, Ritchie E, Silver RT, Kessler C, Winton E, Finazzi MC, Rambaldi A, Vannucchi AM, Leibowitz D, Rondelli D, Arcasoy MO, Catchatourian R, Vadakara J, Rosti V, Hexner E, Kremyanskaya M, Sandy L, Tripodi J, Najfeld V, Farnoud N, Papaemmanuil E, Salama M, Singer-Weinberg R, Rampal R, Goldberg JD, Barbui T, Mesa R, Dueck AC, Hoffman R.

Blood. 2019 Oct 31;134(18):1498-1509. doi: 10.1182/blood.2019000428.

3.

Macrocystic (Mammary Analogue) Secretory Carcinoma: An Unusual Variant and a Pitfall in the Differential Diagnosis of Cystic Lesions in the Head and Neck.

Hernandez-Prera JC, Holmes BJ, Valentino A, Harshan M, Bacchi CE, Petersson F, Liu KK, Najfeld V, Wenig BM.

Am J Surg Pathol. 2019 Nov;43(11):1483-1492. doi: 10.1097/PAS.0000000000001309.

PMID:
31464708
4.

A prospective evaluation of pegylated interferon alfa-2a therapy in patients with polycythemia vera and essential thrombocythemia with a prior splanchnic vein thrombosis.

Mascarenhas J, Kosiorek H, Prchal J, Yacoub A, Berenzon D, Baer MR, Ritchie E, Silver RT, Kessler C, Winton E, Finazzi MC, Rambaldi A, Vannucchi AM, Leibowitz D, Rondelli D, Arcasoy MO, Catchatourian R, Vadakara J, Rosti V, Hexner E, Kremyanskaya M, Sandy L, Tripodi J, Najfeld V, Farnoud N, Salama ME, Weinberg RS, Rampal R, Goldberg JD, Mesa R, Dueck AC, Hoffman R.

Leukemia. 2019 Dec;33(12):2974-2978. doi: 10.1038/s41375-019-0524-7. Epub 2019 Jul 30. No abstract available.

PMID:
31363161
5.

Oral idasanutlin in patients with polycythemia vera.

Mascarenhas J, Lu M, Kosiorek H, Virtgaym E, Xia L, Sandy L, Mesa R, Petersen B, Farnoud N, Najfeld V, Rampal R, Dueck A, Hoffman R.

Blood. 2019 Aug 8;134(6):525-533. doi: 10.1182/blood.2018893545. Epub 2019 Jun 5.

6.

Multipotent fetal-derived Cdx2 cells from placenta regenerate the heart.

Vadakke-Madathil S, LaRocca G, Raedschelders K, Yoon J, Parker SJ, Tripodi J, Najfeld V, Van Eyk JE, Chaudhry HW.

Proc Natl Acad Sci U S A. 2019 Jun 11;116(24):11786-11795. doi: 10.1073/pnas.1811827116. Epub 2019 May 20.

7.

A Novel t(1;9)(p36;p24.1) JAK2 Translocation and Review of the Literature.

Levavi H, Tripodi J, Marcellino B, Mascarenhas J, Jones AV, Cross NCP, Gruenstein D, Najfeld V.

Acta Haematol. 2019;142(2):105-112. doi: 10.1159/000498945. Epub 2019 May 7.

8.

Comparing the epidemiology, clinical characteristics and prognostic factors of acute myeloid leukemia with and without acute promyelocytic leukemia.

Kamath GR, Tremblay D, Coltoff A, Caro J, Lancman G, Bhalla S, Najfeld V, Mascarenhas J, Taioli E.

Carcinogenesis. 2019 Jul 4;40(5):651-660. doi: 10.1093/carcin/bgz014.

PMID:
30715157
9.

Impact of High-Molecular-Risk Mutations on Transplantation Outcomes in Patients with Myelofibrosis.

Tamari R, Rapaport F, Zhang N, McNamara C, Kuykendall A, Sallman DA, Komrokji R, Arruda A, Najfeld V, Sandy L, Medina J, Litvin R, Famulare CA, Patel MA, Maloy M, Castro-Malaspina H, Giralt SA, Weinberg RS, Mascarenhas JO, Mesa R, Rondelli D, Dueck AC, Levine RL, Gupta V, Hoffman R, Rampal RK.

Biol Blood Marrow Transplant. 2019 Jun;25(6):1142-1151. doi: 10.1016/j.bbmt.2019.01.002. Epub 2019 Jan 6.

PMID:
30625392
10.

Differences in the clinical and genetic profile of Hispanic and non-Hispanic acute myeloid leukemia patients.

Kamath GR, Tremblay D, Coltoff A, Caro J, Lancman G, Bhalla S, Najfeld V, Mascarenhas J, Taioli E.

Leuk Res. 2019 Feb;77:1-4. doi: 10.1016/j.leukres.2018.12.006. Epub 2018 Dec 19. No abstract available.

PMID:
30594101
11.

Advanced forms of MPNs are accompanied by chromosomal abnormalities that lead to dysregulation of TP53.

Marcellino BK, Hoffman R, Tripodi J, Lu M, Kosiorek H, Mascarenhas J, Rampal RK, Dueck A, Najfeld V.

Blood Adv. 2018 Dec 26;2(24):3581-3589. doi: 10.1182/bloodadvances.2018024018.

12.

Safety and efficacy of combined ruxolitinib and decitabine in accelerated and blast-phase myeloproliferative neoplasms.

Rampal RK, Mascarenhas JO, Kosiorek HE, Price L, Berenzon D, Hexner E, Abboud CN, Kremyanskaya M, Weinberg RS, Salama ME, Menghrajani K, Najfeld V, Sandy L, Heaney ML, Levine RL, Mesa RA, Dueck AC, Goldberg JD, Hoffman R.

Blood Adv. 2018 Dec 26;2(24):3572-3580. doi: 10.1182/bloodadvances.2018019661.

13.

Genomic characterization of spleens in patients with myelofibrosis.

Zimran E, Tripodi J, Rampal R, Rappoport F, Zirkiev S, Hoffman R, Najfeld V.

Haematologica. 2018 Oct;103(10):e446-e449. doi: 10.3324/haematol.2018.193763. Epub 2018 May 10. No abstract available.

14.

Myeloid/lymphoid neoplasms with FGFR1 rearrangement.

Strati P, Tang G, Duose DY, Mallampati S, Luthra R, Patel KP, Hussaini M, Mirza AS, Komrokji RS, Oh S, Mascarenhas J, Najfeld V, Subbiah V, Kantarjian H, Garcia-Manero G, Verstovsek S, Daver N.

Leuk Lymphoma. 2018 Jul;59(7):1672-1676. doi: 10.1080/10428194.2017.1397663. Epub 2017 Nov 9.

PMID:
29119847
15.

A phase II study of panobinostat in patients with primary myelofibrosis (PMF) and post-polycythemia vera/essential thrombocythemia myelofibrosis (post-PV/ET MF).

Mascarenhas J, Sandy L, Lu M, Yoon J, Petersen B, Zhang D, Ye F, Newsom C, Najfeld V, Hochman T, Goldberg JD, Hoffman R.

Leuk Res. 2017 Feb;53:13-19. doi: 10.1016/j.leukres.2016.11.015. Epub 2016 Nov 30.

PMID:
27930945
16.

Reappraising hyalinizing clear cell carcinoma: A population-based study with molecular confirmation.

Hernandez-Prera JC, Kwan R, Tripodi J, Chiosea S, Cordon-Cardo C, Najfeld V, Demicco EG.

Head Neck. 2017 Mar;39(3):503-511. doi: 10.1002/hed.24637. Epub 2016 Nov 29.

PMID:
27898192
17.

Outcome of Allogeneic Hematopoietic Stem Cell Transplantation for Patients with Chronic and Advanced Phase Myelofibrosis.

Keyzner A, Han S, Shapiro S, Moshier E, Schorr E, Petersen B, Najfeld V, Kremyanskaya M, Isola L, Hoffman R, Mascarenhas J.

Biol Blood Marrow Transplant. 2016 Dec;22(12):2180-2186. doi: 10.1016/j.bbmt.2016.08.029. Epub 2016 Sep 3.

18.

Analysis of ALK gene in 133 patients with breast cancer revealed polysomy of chromosome 2 and no ALK amplification.

Hanna MG, Najfeld V, Irie HY, Tripodi J, Nayak A.

Springerplus. 2015 Aug 21;4:439. doi: 10.1186/s40064-015-1235-9. eCollection 2015.

19.

Double minute amplification of mutant PDGF receptor α in a mouse glioma model.

Zou H, Feng R, Huang Y, Tripodi J, Najfeld V, Tsankova NM, Jahanshahi M, Olson LE, Soriano P, Friedel RH.

Sci Rep. 2015 Feb 16;5:8468. doi: 10.1038/srep08468.

20.

Phase I dose escalation study of lestaurtinib in patients with myelofibrosis.

Hexner EO, Mascarenhas J, Prchal J, Roboz GJ, Baer MR, Ritchie EK, Leibowitz D, Demakos EP, Miller C, Siuty J, Kleczko J, Price L, Jeschke G, Weinberg R, Basu T, Pahl HL, Orazi A, Najfeld V, Marchioli R, Goldberg JD, Silverman LR, Hoffman R.

Leuk Lymphoma. 2015;56(9):2543-51. doi: 10.3109/10428194.2014.1001986. Epub 2015 Feb 20.

21.

JAK2 inhibitors do not affect stem cells present in the spleens of patients with myelofibrosis.

Wang X, Ye F, Tripodi J, Hu CS, Qiu J, Najfeld V, Novak J, Li Y, Rampal R, Hoffman R.

Blood. 2014 Nov 6;124(19):2987-95. doi: 10.1182/blood-2014-02-558015. Epub 2014 Sep 5.

22.

Cytogenetically normal acute myeloid leukemia with a novel KIT mutation in exon 11 G565V developing a sole trisomy 13 at relapse: a clinical dilemma.

Nieto MJ, Scalise A, Najfeld V.

Acta Haematol. 2015;133(1):1-5. doi: 10.1159/000360389. Epub 2014 Jun 21.

PMID:
24968822
23.

MPD-RC 101 prospective study of reduced-intensity allogeneic hematopoietic stem cell transplantation in patients with myelofibrosis.

Rondelli D, Goldberg JD, Isola L, Price LS, Shore TB, Boyer M, Bacigalupo A, Rambaldi A, Scarano M, Klisovic RB, Gupta V, Andreasson B, Mascarenhas J, Wetzler M, Vannucchi AM, Prchal JT, Najfeld V, Orazi A, Weinberg RS, Miller C, Barosi G, Silverman LR, Prosperini G, Marchioli R, Hoffman R.

Blood. 2014 Aug 14;124(7):1183-91. doi: 10.1182/blood-2014-04-572545. Epub 2014 Jun 24.

24.

BCR-ABL1 is a secondary event after JAK2V617F in patients with polycythemia vera who develop chronic myeloid leukemia.

Wang X, Tripodi J, Kremyanskaya M, Blouin A, Roda P, Hoffman R, Najfeld V.

Blood. 2013 Feb 14;121(7):1238-9. doi: 10.1182/blood-2012-11-467787. No abstract available.

PMID:
23411734
25.

A phase I study of panobinostat (LBH589) in patients with primary myelofibrosis (PMF) and post-polycythaemia vera/essential thrombocythaemia myelofibrosis (post-PV/ET MF).

Mascarenhas J, Lu M, Li T, Petersen B, Hochman T, Najfeld V, Goldberg JD, Hoffman R.

Br J Haematol. 2013 Apr;161(1):68-75. doi: 10.1111/bjh.12220. Epub 2013 Jan 21.

PMID:
23330839
26.

A case report of chronic myelogenous leukemia in a patient with multiple myeloma and a review of the literature.

Ragupathi L, Najfeld V, Chari A, Petersen B, Jagannath S, Mascarenhas J.

Clin Lymphoma Myeloma Leuk. 2013 Apr;13(2):175-9. doi: 10.1016/j.clml.2012.09.010. Epub 2012 Nov 15. Review. No abstract available.

PMID:
23168212
27.

Spleens of myelofibrosis patients contain malignant hematopoietic stem cells.

Wang X, Prakash S, Lu M, Tripodi J, Ye F, Najfeld V, Li Y, Schwartz M, Weinberg R, Roda P, Orazi A, Hoffman R.

J Clin Invest. 2012 Nov;122(11):3888-99.

28.

Proposed criteria for response assessment in patients treated in clinical trials for myeloproliferative neoplasms in blast phase (MPN-BP): formal recommendations from the post-myeloproliferative neoplasm acute myeloid leukemia consortium.

Mascarenhas J, Heaney ML, Najfeld V, Hexner E, Abdel-Wahab O, Rampal R, Ravandi F, Petersen B, Roboz G, Feldman E, Podoltsev N, Douer D, Levine R, Tallman M, Hoffman R; Post-myeloproliferative neoplasm acute myeloid leukemia consortium.

Leuk Res. 2012 Dec;36(12):1500-4. doi: 10.1016/j.leukres.2012.08.013. Epub 2012 Aug 28.

29.

Combination treatment in vitro with Nutlin, a small-molecule antagonist of MDM2, and pegylated interferon-α 2a specifically targets JAK2V617F-positive polycythemia vera cells.

Lu M, Wang X, Li Y, Tripodi J, Mosoyan G, Mascarenhas J, Kremyanskaya M, Najfeld V, Hoffman R.

Blood. 2012 Oct 11;120(15):3098-105. doi: 10.1182/blood-2012-02-410712. Epub 2012 Aug 7.

30.

An unusual case of donor-derived myelodysplastic syndrome following double-unit umbilical cord blood transplantation in acute lymphoblastic leukemia.

Cotter R, Najfeld V, Isola L, Del Toro G, Roman E, Petersen B, Mascarenhas J.

Am J Hematol. 2012 Sep;87(9):931-3. doi: 10.1002/ajh.23260. Epub 2012 Jun 22.

31.

Oncogene-mediated alterations in chromatin conformation.

Rickman DS, Soong TD, Moss B, Mosquera JM, Dlabal J, Terry S, MacDonald TY, Tripodi J, Bunting K, Najfeld V, Demichelis F, Melnick AM, Elemento O, Rubin MA.

Proc Natl Acad Sci U S A. 2012 Jun 5;109(23):9083-8. doi: 10.1073/pnas.1112570109. Epub 2012 May 21.

32.

Development of myelodysplastic syndrome and acute myeloid leukemia 15 years after hydroxyurea use in a patient with sickle cell anemia.

Baz W, Najfeld V, Yotsuya M, Talwar J, Terjanian T, Forte F.

Clin Med Insights Oncol. 2012;6:149-52. doi: 10.4137/CMO.S8810. Epub 2012 Mar 7.

33.

Fetal cells traffic to injured maternal myocardium and undergo cardiac differentiation.

Kara RJ, Bolli P, Karakikes I, Matsunaga I, Tripodi J, Tanweer O, Altman P, Shachter NS, Nakano A, Najfeld V, Chaudhry HW.

Circ Res. 2012 Jan 6;110(1):82-93. doi: 10.1161/CIRCRESAHA.111.249037. Epub 2011 Nov 14. Erratum in: Circ Res. 2015 Nov 6;117(11):e91.

34.

Multiploid inheritance of HIV-1 during cell-to-cell infection.

Del Portillo A, Tripodi J, Najfeld V, Wodarz D, Levy DN, Chen BK.

J Virol. 2011 Jul;85(14):7169-76. doi: 10.1128/JVI.00231-11. Epub 2011 May 4.

35.

Development of t(8;21) and RUNX1-RUNX1T1 in the Philadelphia-positive clone of a patient with chronic myelogenous leukemia: additional evidence for multiple steps involved in disease progression.

Najfeld V, Wisch N, Mascarenhas J, Issa L, Tripodi J, Sidhu M, Hoffman R.

Cancer Genet. 2011 Mar;204(3):165-70. doi: 10.1016/j.cancergencyto.2010.09.001.

PMID:
21504717
36.

Down-regulation of stathmin expression is required for megakaryocyte maturation and platelet production.

Iancu-Rubin C, Gajzer D, Tripodi J, Najfeld V, Gordon RE, Hoffman R, Atweh GF.

Blood. 2011 Apr 28;117(17):4580-9. doi: 10.1182/blood-2010-09-305540. Epub 2011 Mar 1.

37.

Frequency of heterozygous TET2 deletions in myeloproliferative neoplasms.

Tripodi J, Hoffman R, Najfeld V, Weinberg R.

Cancer Manag Res. 2010 Sep 17;2:219-23. doi: 10.2147/CMR.S12829.

38.

Letter to the editor regarding the article "Chromosome abnormalities additional to the Philadelphia chromosome at the diagnosis of chronic myelogenous leukemia: pathogenic and prognostic implications".

Najfeld V.

Cancer Genet Cytogenet. 2010 Dec;203(2):355-6; author reply 357-8. doi: 10.1016/j.cancergencyto.2010.09.011. No abstract available.

PMID:
21156260
39.

Sequential treatment of CD34+ cells from patients with primary myelofibrosis with chromatin-modifying agents eliminate JAK2V617F-positive NOD/SCID marrow repopulating cells.

Wang X, Zhang W, Tripodi J, Lu M, Xu M, Najfeld V, Li Y, Hoffman R.

Blood. 2010 Dec 23;116(26):5972-82. doi: 10.1182/blood-2010-02-269696. Epub 2010 Sep 21.

40.

Jumping translocations of the long arms of chromosome 1 in myeloid malignancies is associated with a high risk of transformation to acute myeloid leukaemia.

Najfeld V, Tripodi J, Scalise A, Silverman LR, Silver RT, Fruchtman S, Hoffman R.

Br J Haematol. 2010 Nov;151(3):288-91. doi: 10.1111/j.1365-2141.2010.08355.x. Epub 2010 Aug 25. No abstract available.

PMID:
20738298
41.

Ring chromosome 18 abnormality in acute myelogenous leukemia: the clinical dilemma.

Sivendran S, Gruenstein S, Malone AK, Najfeld V.

J Hematol Oncol. 2010 Jul 22;3:25. doi: 10.1186/1756-8722-3-25.

42.

Therapeutic options for patients with myelofibrosis in blast phase.

Mascarenhas J, Navada S, Malone A, Rodriguez A, Najfeld V, Hoffman R.

Leuk Res. 2010 Sep;34(9):1246-9. doi: 10.1016/j.leukres.2010.05.008.

PMID:
20627294
43.

Transcriptional profiling of polycythemia vera identifies gene expression patterns both dependent and independent from the action of JAK2V617F.

Berkofsky-Fessler W, Buzzai M, Kim MK, Fruchtman S, Najfeld V, Min DJ, Costa FF, Bischof JM, Soares MB, McConnell MJ, Zhang W, Levine R, Gilliland DG, Calogero R, Licht JD.

Clin Cancer Res. 2010 Sep 1;16(17):4339-52. doi: 10.1158/1078-0432.CCR-10-1092. Epub 2010 Jul 2.

44.

Long-term storage does not alter functionality of in vitro generated human erythroblasts: implications for ex vivo generated erythroid transfusion products.

Migliaccio G, Sanchez M, Leblanc A, Masiello F, Tirelli V, Migliaccio AR, Najfeld V, Whitsett C.

Transfusion. 2009 Dec;49(12):2668-79. doi: 10.1111/j.1537-2995.2009.02329.x. Epub 2009 Jul 29.

PMID:
19659677
45.

Clonal analyses define the relationships between chromosomal abnormalities and JAK2V617F in patients with Ph-negative myeloproliferative neoplasms.

Wang X, LeBlanc A, Gruenstein S, Xu M, Mascarenhas J, Panzera B, Wisch N, Parker C, Goldberg JD, Prchal J, Hoffman R, Najfeld V.

Exp Hematol. 2009 Oct;37(10):1194-200. doi: 10.1016/j.exphem.2009.07.003. Epub 2009 Jul 15.

PMID:
19615425
46.

Involvement of mast cells by the malignant process in patients with Philadelphia chromosome negative myeloproliferative neoplasms.

Wang J, Ishii T, Zhang W, Sozer S, Dai Y, Mascarenhas J, Najfeld V, Zhao ZJ, Hoffman R, Wisch N, Xu M.

Leukemia. 2009 Sep;23(9):1577-86. doi: 10.1038/leu.2009.85. Epub 2009 Apr 23.

PMID:
19387466
47.

Duplication and triplication of der(21)t(8;21)(q22;q22) in acute myeloid leukemia.

Mikulasovich M, LeBlanc A, Scalise A, Manwani D, Keyzner A, Najfeld V.

Cancer Genet Cytogenet. 2009 Jan 15;188(2):83-7. doi: 10.1016/j.cancergencyto.2008.10.004.

PMID:
19100510
48.

Focal gains of VEGFA and molecular classification of hepatocellular carcinoma.

Chiang DY, Villanueva A, Hoshida Y, Peix J, Newell P, Minguez B, LeBlanc AC, Donovan DJ, Thung SN, Solé M, Tovar V, Alsinet C, Ramos AH, Barretina J, Roayaie S, Schwartz M, Waxman S, Bruix J, Mazzaferro V, Ligon AH, Najfeld V, Friedman SL, Sellers WR, Meyerson M, Llovet JM.

Cancer Res. 2008 Aug 15;68(16):6779-88. doi: 10.1158/0008-5472.CAN-08-0742.

49.

HIV-1 Vpr inhibits cytokinesis in human proximal tubule cells.

Rosenstiel PE, Gruosso T, Letourneau AM, Chan JJ, LeBlanc A, Husain M, Najfeld V, Planelles V, D'Agati VD, Klotman ME, Klotman PE.

Kidney Int. 2008 Oct;74(8):1049-58. doi: 10.1038/ki.2008.303. Epub 2008 Jul 9.

Supplemental Content

Loading ...
Support Center